Results 201 to 210 of about 80,269 (322)
Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection [PDF]
Brendan J. Kelly, Pablo Tebas
openalex +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
The application of fecal microbiota transplantation in Parkinson's disease. [PDF]
Wang B, Ma D, Li N, Luo T.
europepmc +1 more source
Our study demonstrated that TGF‐β1 activated MAPK signalling pathway and promoted the MMT and secretion of CCL17 under CD‐associated intestinal inflammatory conditions. AMSC‐sEVs can deliver MFGE8, which inhibits MMT and CCL17‐mediated Treg recruitment by suppressing the MAPK signalling pathway, thereby alleviating intestinal fibrosis.
Minghao Xie +6 more
wiley +1 more source
Brief Report: Can Fecal Microbiota Transplantation Treat Depression? [PDF]
Benterkia S, Blythe J.
europepmc +1 more source
Abstract Aims Obesity and type 2 diabetes mellitus (T2DM) are among the leading global health challenges of the 21st century. While caloric restriction remains the cornerstone of weight loss interventions, ketogenic diets (KD), characterised by low carbohydrate and high fat intake, have been shown to improve metabolic health partly by modulating the ...
June Stone +5 more
wiley +1 more source
Fecal microbiota transplantation (FMT): application and future direction [PDF]
Nawaf Rahi Alshammari
openalex +1 more source
Fecal Microbiota Transplantation in 2025: Two Steps Forward, One Step Back. [PDF]
Miller CB, Bader GA, Kay CL.
europepmc +1 more source
ABSTRACT The interplay between the commensal microbiota and the mammalian immune system may influence the outcomes of T cell‐driven cancer immunotherapies. However, clinical studies supporting microbiota‐based interventions in chimeric antigen receptor T‐cell (CAR‐T) therapy remain scarce.
Rafael Hernani +22 more
wiley +1 more source

